<DOC>
	<DOCNO>NCT00020657</DOCNO>
	<brief_summary>RATIONALE : Antiemetic drug may help reduce prevent nausea vomit patient treated chemotherapy . PURPOSE : This randomized phase III trial compare well different antiemetic drug work prevent delay nausea chemotherapy patient cancer .</brief_summary>
	<brief_title>Comparison Antiemetic Drugs Preventing Delayed Nausea After Chemotherapy Patients With Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare effectiveness 5 hydroxytryptamine 3 ( 5-HT3 ) receptor antagonist antiemetic v prochlorperazine control delay nausea chemotherapy patient chemotherapy-naive cancer . - Compare effectiveness prochlorperazine administer preventive v need basis control delay nausea chemotherapy patient . - Compare quality life patient treat 5-HT3 receptor antagonist antiemetic v prochlorperazine . - Compare quality life patient treat prochlorperazine administer preventive v need basis . OUTLINE : This randomize , multicenter study . Patients stratify accord center . Patients receive schedule chemotherapy regimen contain doxorubicin schedule oral 5 hydroxytryptamine 3 receptor antagonist antiemetic ( ondansetron , granisetron , tropisetron , dolasetron mesylate ) combine dexamethasone day 1 . Patients randomize 1 3 antiemetic arm . - Arm I : Patients receive oral prochlorperazine every 8 hour day 2 3 . - Arm II : Patients receive oral ondansetron every 12 hour , oral granisetron every 12 hour , oral dolasetron mesylate either day every 12 hour day 2 3 . - Arm III : Patients receive oral prochlorperazine need , 4 time per day , day 2 3 . Quality life assess baseline day 4 . PROJECTED ACCRUAL : A total 670 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<mesh_term>Prochlorperazine</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<mesh_term>Dolasetron</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis cancer chemotherapy regimen contain doxorubicin ( adjuvant , neoadjuvant , curative , palliative intent ) schedule Scheduled chemotherapy regimen must include follow : Multiple dos doxorubicin , dacarbazine , hexamethylmelamine , nitrosoureas , streptozocin Doxorubicin HydroCloride liposome cisplatin Scheduled chemotherapy regimen may contain agent , list , administer orally , IV , IV continuously 1 multiple day Must schedule receive 5 hydroxytryptamine 3 ( 5HT3 ) receptor antagonist antiemetic ( ondansetron , granisetron , tropisetron , dolasetron mesylate ) dexamethasone concurrently doxorubicin No clinical evidence impend bowel obstruction No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent interferon Chemotherapy : See Disease Characteristics No prior chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : Concurrent rescue medication ( appropriate ) control symptom cause cancer treatment allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>nausea vomit</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>